Article Text

Download PDFPDF
Azithromycin for ocular toxoplasmosis
  1. Aniki Rothova,
  2. Lotje E H Bosch-Driessen,
  3. Ninette H van Loon,
  4. W Frits Treffers
  1. Department of Ophthalmology, FC Donders Institute, Academic Hospital Utrecht, Netherlands
  1. Aniki Rothova, MD, F C Donders Institute, Department of Ophthalmology, Academic Hospital Utrecht, PO Box 85 500, 3508 GA Utrecht, Netherlands.


AIMS To investigate the efficacy of azithromycin in patients with ocular toxoplasmosis.

METHODS 11 immunocompetent patients with ocular toxoplasmosis were treated with azithromycin (500 mg the first day, followed by 250 mg/day for 5 weeks). Ocular and systemic examinations were performed during active retinitis episodes and all patients were followed for at least 1 year.

RESULTS The intraocular inflammation disappeared within 4 weeks in seven patients, including two cases with progressive retinitis despite previous treatment with pyrimethamine, sulphadiazine, and folinic acid. Recurrence of retinitis occurred in three patients (27%) within the first year of follow up. No systemic side effects of azithromycin were encountered.

CONCLUSION These results indicate that although azithromycin cannot prevent recurrent disease it may be an effective alternative for patients with ocular toxoplasmosis who cannot tolerate standard therapies.

  • azithromycin
  • ocular toxoplasmosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.